Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement
Spuls, Ph.I.; Gerbens, L.A.A.; Simpson, E.; Apfelbacher, C.J.; Chalmers, J.R.; Thomas, K.S.; Prinsen, C.A.C.; Kobyletzki, L.B. von; Singh, J.A.; Williams, Hywel C.; Schmitt, J.
Professor KIM THOMAS KIM.THOMAS@NOTTINGHAM.AC.UK
Professor of Applied Dermatology Research
L.B. von Kobyletzki
HYWEL WILLIAMS email@example.com
Professor of Dermato-Epidemiology
Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has defined four core outcome domains for a core outcome set (COS) to be measured in all atopic eczema (AE) trials to ensure cross-trial comparison: clinical signs, symptoms, quality of life and longterm control.
Objectives: The aim of this paper is to report on the consensus process that was used to select the core instrument to consistently assess symptoms in all future AE trials.
Methods: Following the HOME roadmap, two systematic reviews were performed which identified three instruments that had sufficient evidence of validity, reliability, and feasibility to be considered for the final COS.
Results: At the 4th international HOME meeting there was broad consensus among all stakeholders that the Patient-Oriented Eczema Measure (POEM) should be used as the core instrument (87.5% agreed, 9.4% unsure, 3.1% disagreed).
Conclusions: All relevant stakeholders are encouraged to use POEM as the chosen instrument to measure the core domain of symptoms in all future AE clinical trials. Other instruments of interest can be used in addition to POEM.
Spuls, P., Gerbens, L., Simpson, E., Apfelbacher, C., Chalmers, J., Thomas, K., …Schmitt, J. (2017). Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. British Journal of Dermatology, 176(4), 979-984. https://doi.org/10.1111/bjd.15179
|Journal Article Type||Article|
|Acceptance Date||Nov 2, 2016|
|Online Publication Date||Nov 17, 2016|
|Publication Date||Apr 1, 2017|
|Deposit Date||Jan 5, 2017|
|Publicly Available Date||Jan 5, 2017|
|Journal||British Journal of Dermatology|
|Peer Reviewed||Peer Reviewed|
|Copyright Statement||Copyright information regarding this work can be found at the following address: http://eprints.nottingham.ac.uk/end_user_agreement.pdf|
|Additional Information||This is the peer reviewed version of the following article Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement / Ph.I. Spuls, L.A.A. Gerbens, E. Simpson, C.J. Apfelbacher, J.R. Chalmers, K.S. Thomas, C.A.C. Prinsen, L.B. von Kobyletzki, J.A. Singh, H.C. Williams, J. Schmitt and The HOME initiative collaborators, which has been published in final form at http://dx.doi.org/10.1111/bjd.15179. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.|
POEM a core instrument to measure symptoms in clinical trials - HOME Symptoms Statement 290916.pdf
Copyright information regarding this work can be found at the following address: http://eprints.nottingham.ac.uk/end_user_agreement.pdf